|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
Q2 FY2014
As of Jun 30, 2014
|
Q1 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Available-for-sale Securities, Amortized Cost Basis | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventory, net | ||||||||||||||||||||
| Deferred costs | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Partner commissions payable | ||||||||||||||||||||
| Accrued royalties payable | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Capital lease obligation, current | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Capital lease obligation, non-current | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Preferred stock, $0.0001 par value: 10,000 shares authorized as of September 30, 2018 and December 31, 2017; none issued and outstanding | ||||||||||||||||||||
| Common stock, $0.0001 par value — 500,000 shares authorized and 17,153 and 16,932 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively | ||||||||||||||||||||
| Treasury stock; none at December 31, 2016 and 50 shares at December 31, 2015 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| TOTAL STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
Loading...
